Advances in the Use of CMR in Subclinical Diabetic Cardiomyopathy
CT Lilun yu yingyong yanjiu · 2023-11 · 32 (6) · 836-842
DOI: 10.15953/j.ctta.2022.255 ↗Kurz gefasst
Fachartikel in der Zeitschrift CT Lilun yu yingyong yanjiu, 2023-11. Verfasst von Guorong LI und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Diabetic cardiomyopathy (DCM) presents as myocardial fibrosis, left ventricular hypertrophy, and myocardial diastolic abnormalities. Cardiac magnetic resonance (CMR) technology can quickly and accurately determine the myocardial structure and cardiac function of diabetic patients and plays a crucial role in the diagnostic and prognostic evaluation of subclinical DCM. Evaluation of subclinical DCM using CMR technology primarily involves cardiac magnetic resonance-feature tracking (CMR-FT), magnetic resonance spectroscopy (MRS), T1 mapping technology, and magnetic resonance myocardial perfusion imaging. This paper reviews the research progress of CMR technology in the diagnosis of subclinical diabetic cardiomyopathy.
Schlagwörter
Zitieren
APA
LI, G., SUN, Y., & ZHANG, T. (2023). Advances in the Use of CMR in Subclinical Diabetic Cardiomyopathy. CT Lilun yu yingyong yanjiu, 32(6), 836-842. https://doi.org/10.15953/j.ctta.2022.255
Vancouver
LI G, SUN Y, ZHANG T. Advances in the Use of CMR in Subclinical Diabetic Cardiomyopathy. CT Lilun yu yingyong yanjiu. 2023;32(6):836-842. doi:10.15953/j.ctta.2022.255
BibTeX
@article{LI2023,
author = {LI, Guorong and SUN, Yang and ZHANG, Tingting},
title = {Advances in the Use of CMR in Subclinical Diabetic Cardiomyopathy},
journal = {CT Lilun yu yingyong yanjiu},
year = {2023},
volume = {32},
number = {6},
pages = {836--842},
doi = {10.15953/j.ctta.2022.255}
}
EUVIMED